The VJ Sessions | VJHemOnc

The VJ Sessions have brought together leading experts virtually to help continue the valuable international collaborations in diseases such as Multiple Myeloma, CLL, AML, Lymphoma, MDS and MPNs. You can view our collection of webinar sessions below at your convenience, as well as being able to listen to podcasts of each session on the go.

Multiple Myeloma

Multiple Myeloma

iwCAR-T 2022 day 3 highlights with a focus on myeloma

Krina Patel, Suzanne Trudel, Yi Lin, Frederick Locke

Myeloma updates from EHA 2022

Mohamad Mohty, Saad Usmani

Myeloma treatment in the UK

PIKfyve, RAS, the epigenome & PROTAC therapy

Paola Neri, Lawrence Boise

Genomics in the age of I-O

Gareth Morgan, Francesco Maura, Leo Rasche

Using single-cell analysis to tackle myeloma

Irene Ghobrial, Yael Cohen, Eileen Boyle, Rodger Tiedemann

Novel targets in 2022

Faith Davies, Charlotte Pawlyn, Hearn Jay Cho

Day 1 highlights from Myeloma 2022

Keith Stewart, Gareth Morgan, Faith Davies

T-Cell engagers

Hermann Einsele, Nina Shah, Thomas Martin

Day 2 highlights from Myeloma 2022

Gareth Morgan, Rafael Fonseca, Leif Bergsagel, Keith Stewart

Post-ASH 2021

Graham Jackson, Rakesh Popat

A deep dive into screening for precursor conditions

Irene Ghobrial, Sigurdur Kristinsson

Post-EHA/ASCO 2021

Noopur Raje, Katja Weisel, Nina Shah, Yi Lin

The patient perspective

Mohamad Mohty, , , ,

Post-COMy 2021

Mohamad Mohty, Thierry Facon, Alessandra Larocca

Post-ASH 2020 UK

Karthik Ramasamy, Rakesh Popat

Post-ASH 2020

Maria-Victoria Mateos, Nina Shah, Thomas Martin

Myeloma & COVID-19

Paul Richardson, Evangelos Terpos, Maria-Victoria Mateos, Ajai Chari

COMy & EHA 2020

Francesca Gay, Saad Usmani, Mohamad Mohty

Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia (CLL)

CLL updates from iwCAR-T 2022

John Gribben, Mazyar Shadman, Saar Gill

Exploring key ASH 2021 clinical trials in the frontline and R/R setting

Adam Kittai, Jennifer Woyach

Post-EHA/ICML 2021

Paolo Ghia, Susan O’Brien, Lydia Scarfò, Othman Al-Sawaf

Post-ASH 2020

John Gribben, Alessandra Tedeschi, Meghan Thompson, Matthew Davids

ASCO & EHA 2020

John Gribben, Susan O’Brien, Matthew Davids, Barbara Eichhorst

Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

AML updates from iwCAR-T 2022

Saar Gill, John DiPersio, Rizwan Romee

Updates in FLT3+ from ASH 2021

Naval Daver, Eunice Wang

Post-EHA/ASCO 2021

Naval Daver, Eunice Wang, Felicitas Thol

Post-ASH 2020

Naval Daver, David Sallman, Eunice Wang, Amir Fathi

FLT3-Mutated AML

Naval Daver, Amir Fathi, Jessica Altman, Eunice Wang

Venetoclax-Based Regimens

Naval Daver, Courtney DiNardo, Marina Konopleva, Andrew Wei

IDH Inhibitors

Amir Fathi, Stéphane de Botton, Daniel Pollyea

Immunotherapy

Marion Subklewe, Naval Daver, David Sallman, Amer Zeidan

EHA & ASCO 2020

Naval Daver, Marion Subklewe, Andrew Wei, Amir Fathi

Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

iwMDS 2022

Mrinal Patnaik, Zhuoer Xie, Eric Padron, Amer Zeidan, Valeria Santini, Rena Buckstein, Hetty Carraway, Olatoyosi Odenike, Justin Taylor, Aziz Nazha, Jane Churpek, Rafael Bejar, Robert Hasserjian, Alan List, Uwe Platzbecker, Daniel Starczynowski, David Sallman

The impact of AI in MDS

Amer Zeidan, Aziz Nazha, Anne Sophie Kubasch

What did ASH 2021 mean for MDS?

David Sallman, Andrew Brunner

Post-EHA/ASCO 2021

Amer Zeidan, Andrew Wei, David Sallman

Women in Science

Amer Zeidan, Valeria Santini, Eva Hellström-Lindberg

Diagnosis & Prognosis

Giants in MDS

Amer Zeidan, Peter Greenberg, Mario Cazzola, John Bennett, Ghulam Mufti

Global Perspectives

Amer Zeidan, Anne Mwirigi, David Gomez-Almaguer, Mariana Guaraná, Rishi Dhawan, Iman Aboudalle

Post-ASH 2020

Amer Zeidan, Uwe Platzbecker, Jacqueline Garcia

Lower-Risk Disease

Amer Zeidan, Valeria Santini, Rami Komrokji, Olatoyosi Odenike

Latest Updates

Amer Zeidan, Amy DeZern, Michael Savona, Mikkael Sekeres, David Steensma

Myeloproliferative Neoplasms (MPNs)

Myeloproliferative Neoplasms (MPNs)

Key updates from EHA 2022

Ruben Mesa, Claire Harrison, Jean-Jacques Kiladjian

Key updates from ASH 2021

Ruben Mesa, Naveen Pemmaraju

Post-EHA/ASCO 2021

Ruben Mesa, Naveen Pemmaraju

Post-ASH 2020

Ruben Mesa, Srdan Verstovsek, Claire Harrison, Naveen Pemmaraju

2020 Texas MPN Workshop

Naveen Pemmaraju, Ruben Mesa, Claire Harrison

Lymphoma

Lymphoma updates from iwCAR-T 2022

David Maloney, Caron Jacobson, Loretta Nastoupil

CAR-T and lymphoma treatment in the UK

Robin Sanderson, Tobias Menne

Post-ASH 2021

Post-EHA/ICML 2021

Gilles Salles, Nirav Niranjan Shah, Ulrich Jäger, Stephen Ansell

Post-ASH 2020 UK

Graham Collins, Wendy Osborne

Post-ASH 2020

Stephen Ansell, Graham Collins

Amyloidosis

Post-ASH 2020

Morie Gertz, Vaishali Sanchorawala, Raymond Comenzo, Ashutosh Wechalekar

General Hematology

General Hematology

Patient focused CAR-T updates

Kedar Kirtane, Laura Oswald, Heather Jim

iwCAR-T day 2 highlights

John Gribben, Noelle Frey, David Maloney

Post-EBMT for Trainees

Nico Gagelmann, Claire Horgan

Post-EBMT

Nico Gagelmann, Christian Chabannon, Zinaida Perić, Eolia Brissot

CAR-T & Nursing

John Murray, Rose Ellard, Erik Aerts, Michelle Kenyon

Post-ASH 2020

Bruce Levine, Christian Chabannon

COVID & Hematology

Amer Zeidan, John Mascarenhas, Jan Bewersdorf, Rory Shallis